China-based HitGen Inc. (SHA: 688222) has entered into a partnership with compatriot firm Ablink Biotech to integrate their world-leading trillion-level DNA-Encoded Libraries (DELs), a comprehensive small nucleic acid drug discovery and production platform, and a 300 billion-level biopharmaceutical molecule library. The collaboration aims to provide research and development services for antibody-oligonucleotide conjugates (AOCs), with no financial details disclosed.
The partnership focuses on the development of a novel therapeutic drug, the antibody-drug conjugate (ADC), which combines the precise cellular targeting of antibodies with the genetic precision of small nucleic acids, potentially achieving breakthrough therapeutic effects in oncology, neurological diseases, and rare diseases. HitGen and Ablink have previously collaborated on the discovery, optimization, and preparation of antibodies and siRNAs, development of linkers, and production of AOCs. – Flcube.com
